Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness (MARINER)

Sep 13, 2018

Overview : Trial References Spyropoulos AC, Ageno W, Albers GW, et al.; MARINER Investigators. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1805090. Abstract | Full Text Expert Comment Pablo del Castillo Vazquez,  Antoni Martínez-Rubio: Department of Cardiology, University Hospital of... more

Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE Trial)

Aug 27, 2018

Overview : Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE): A Randomised, Double-blind, Placebo-controlled Trial Trial Reference Gaziano JM, Brotons C, Coppolecchia R, et al. Use of Aspirin to Reduce Risk... more

6-Month Versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE): A Randomised, Open-label, Non-inferiority Trial

Mar 20, 2018

Overview : Trial Reference Hahn JY, Song YB, Oh JH, et al; SMART-DATE investigators. 6-Month Versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE): A Randomised, Open-label, Non-inferiority Trial. Lancet. 2018 Mar 9.... more

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

Sep 06, 2017

Overview : Trial Reference Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017 Aug 27 [Epub ahead of print]. Abstract | Full Text   Expert Comment Pablo Avanzas,... more